Publications by authors named "S Al-Sabah"
The lack of standardization in patient-reported outcome measures (PROMs) has made measurement and comparison of quality of life (QoL) outcomes in research focused on obesity treatment challenging. This study reports on the results of the second and third global multidisciplinary Standardizing Quality of life measures in Obesity Treatment (S.Q.
View Article and Find Full Text PDFArticle Synopsis
- COVID-19 poses a higher mortality risk for individuals with diabetes, severe obesity, and cardiovascular disease, potentially due to chronic inflammation linked to type 2 diabetes.
- This study involved 350 patients with type 2 diabetes hospitalized for moderate-severe COVID-19, comparing the effects of pioglitazone against a placebo over 28 days, focusing on severe clinical outcomes and inflammation levels.
- Although pioglitazone reduced certain inflammatory markers, it did not significantly improve outcomes, as more patients treated with it required ICU care and showed no notable difference in CRP reduction compared to those on placebo.
Article Synopsis
- The review highlights the recent approval of resmetirom for treating metabolic dysfunction-associated steatohepatitis (MASH), a liver disease related to obesity, emphasizing its potential impact on global health and the need for a multidisciplinary management approach.* -
- Resmetirom is effective in treating MASH and has received FDA approval, but its safety, potential adverse events, and effectiveness across different populations require further study to optimize patient outcomes.* -
- A comprehensive treatment strategy is recommended, combining resmetirom with lifestyle changes and metabolic and bariatric surgery (MBS), to enhance liver and overall health for individuals suffering from MASH.*
A positively charged residue at the Kv1.1 T1 interface is critical for voltage-dependent activation and gating kinetics.
Am J Physiol Cell Physiol
September 2024
Within the tetramerization domain (T1) of most voltage-gated potassium channels (Kv) are highly conserved charged residues that line the T1-T1 interface. We investigated the Kv1.1 residue R86 located at the narrowest region of the T1 interface.
View Article and Find Full Text PDFObjectives: Bariatric surgery is a well-established treatment for obesity and type 2 diabetes. Tirzepatide, a dual GIP/GLP-1 receptor agonist, has emerged as a promising therapy for type 2 diabetes. This study aimed to compare the effects of bariatric surgery, semaglutide (a GLP-1 receptor agonist), and tirzepatide in Sprague-Dawley rats fed a high-fat diet.
View Article and Find Full Text PDF